Donor-Linked Biomarker Predicts Likelihood of Liver Transplant Success
By LabMedica International staff writers Posted on 31 Aug 2021 |
Image: A healthy human liver. A biomarker linked to the organ donor predicts the likelihood that a transplanted liver will be accepted or rejected by the recipient of the organ (Photo courtesy of Wikimedia Commons)
A recent paper identified a biomarker linked to the organ donor that predicts the likelihood that a transplanted liver will be accepted or rejected by the recipient of the organ.
Compatibility between donor and recipient depends on the similarity of the HLA (human leukocyte antigen) proteins expressed by both. A measure of this similarity is the HLA evolutionary divergence (HED), a continuous metric that quantifies the peptidic differences between two homologous HLA alleles, reflecting the size of the immunopeptide region resented to T-lymphocytes.
In this recent paper, investigators at Assistance Publique, Hôpitaux de Paris, (France) sought to assess the potential effect of donor or recipient HED on liver transplant rejection.
For this study, they accessed the medical records of 1154 adults and 113 children who had a liver transplant between 2004 and 2018. Liver biopsies were done one, two, five, and 10 years after the transplant and in case of liver dysfunction. Donor-specific anti-HLA antibodies (DSAs) were measured in children at the time of biopsy. The HED was calculated using the physicochemical Grantham distance for class I (HLA-A or HLA-B) and class II (HLA-DRB1 or HLA-DQB1) alleles. Grantham's distance depends on three properties: composition, polarity and molecular volume. According to Grantham's distance, the most similar amino acids are leucine and isoleucine and the most distant are cysteine and tryptophan.
The influence of HED on the incidence of liver lesions was analyzed through the inverse probability weighting approach based on covariate balancing, generalized propensity scores.
Data obtained during the study showed that in adults, class I HED of the donor was associated with acute rejection, chronic rejection, and ductopenia of 50% or more but not with other histologic lesions. In children, class I HED of the donor was also associated with acute rejection independent of the presence of DSAs. There was no effect of either donor class II HED or recipient class I or class II HED on the incidence of liver lesions in adults and children. Thus, HED calculated from the HLA alleles of the donor had a much stronger influence on liver transplant success than HLA compatibility. The higher the HED of a donor of liver graft, the more frequent rejection, and this was completely independent of the HLA compatibility of donors and recipients.
These findings allowed the investigators to conclude, “Class I HED of the donor predicts acute or chronic rejection of liver transplant. This novel and accessible prognostic marker could orientate donor selection and guide immunosuppression.”
The study was published in the August 24, 2021, online edition of the journal Annals of Internal Medicine.
Related Links:
Assistance Publique, Hôpitaux de Paris
Compatibility between donor and recipient depends on the similarity of the HLA (human leukocyte antigen) proteins expressed by both. A measure of this similarity is the HLA evolutionary divergence (HED), a continuous metric that quantifies the peptidic differences between two homologous HLA alleles, reflecting the size of the immunopeptide region resented to T-lymphocytes.
In this recent paper, investigators at Assistance Publique, Hôpitaux de Paris, (France) sought to assess the potential effect of donor or recipient HED on liver transplant rejection.
For this study, they accessed the medical records of 1154 adults and 113 children who had a liver transplant between 2004 and 2018. Liver biopsies were done one, two, five, and 10 years after the transplant and in case of liver dysfunction. Donor-specific anti-HLA antibodies (DSAs) were measured in children at the time of biopsy. The HED was calculated using the physicochemical Grantham distance for class I (HLA-A or HLA-B) and class II (HLA-DRB1 or HLA-DQB1) alleles. Grantham's distance depends on three properties: composition, polarity and molecular volume. According to Grantham's distance, the most similar amino acids are leucine and isoleucine and the most distant are cysteine and tryptophan.
The influence of HED on the incidence of liver lesions was analyzed through the inverse probability weighting approach based on covariate balancing, generalized propensity scores.
Data obtained during the study showed that in adults, class I HED of the donor was associated with acute rejection, chronic rejection, and ductopenia of 50% or more but not with other histologic lesions. In children, class I HED of the donor was also associated with acute rejection independent of the presence of DSAs. There was no effect of either donor class II HED or recipient class I or class II HED on the incidence of liver lesions in adults and children. Thus, HED calculated from the HLA alleles of the donor had a much stronger influence on liver transplant success than HLA compatibility. The higher the HED of a donor of liver graft, the more frequent rejection, and this was completely independent of the HLA compatibility of donors and recipients.
These findings allowed the investigators to conclude, “Class I HED of the donor predicts acute or chronic rejection of liver transplant. This novel and accessible prognostic marker could orientate donor selection and guide immunosuppression.”
The study was published in the August 24, 2021, online edition of the journal Annals of Internal Medicine.
Related Links:
Assistance Publique, Hôpitaux de Paris
Latest Molecular Diagnostics News
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer